Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.10.0.1
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 9 Months Ended
Dec. 13, 2017
Aug. 04, 2016
Jun. 15, 2012
Sep. 30, 2018
Sep. 30, 2017
Feb. 16, 2016
George Clinical Services [Member]            
Commitments and Contingencies (Textual)            
Project estimated cost   $ 4,600,000        
Research and development costs       $ 1,600,000 $ 700,000  
Project remaining cost       900,000    
Goodwin [Member]            
Commitments and Contingencies (Textual)            
Research and development costs       1,000,000 1,100,000  
Project remaining cost       1,600,000    
Medpace Inc [Member]            
Commitments and Contingencies (Textual)            
Total project estimated to cost           $ 10,200,000
Research and development costs       2,600,000 2,700,000  
Project remaining cost       3,700,000    
Fred Hutchinson Cancer Research Center (FHCRC) [Member] | License and Sponsored Research Agreement [Member]            
Commitments and Contingencies (Textual)            
Milestones Payments     $ 1,000,000      
Description of royalty payment     Royalty payments of 2% of net sales will be due to FHCRC.      
Incurred expenses       15,000 45,000  
Oak Ridge National Laboratory (ORNL) [Member]            
Commitments and Contingencies (Textual)            
Purchase of materials $ 200,000     $ 200,000 $ 500,000